XML 50 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Organization and Nature of Business (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Organization and Nature of Business [Abstract] |
Schedule of Details of Shareholders | Details of shareholders as of March 31, 2025 are as follows:
Name of Shareholder |  | Number of ordinary share |  |  | Percentage of ownership |
Bellevue Global Life Sciences Investors LLC |  |  | 1,332,500 |  |  |  | 6.91 | %
Bellevue Capital Management Europe AG |  |  | 8,612,634 |  |  |  | 44.68 | %
Bellevue Capital Management LLC |  |  | 3,123,970 |  |  |  | 16.21 | %
Duksung Co.,Ltd. |  |  | 1,420,215 |  |  |  | 7.37 | %
Others |  |  | 4,787,659 |  |  |  | 25.68 | %
Total |  |  | 19,276,978 |  |  |  | 100.00 | %
Schedule of Investments in Subsidiaries | Details of investments in subsidiaries as of March 31, 2025 are as follows:
Name of subsidiary |  | Share capital |  |  | Percentage of ownership |  |  | Principal activities |  | Country of incorporation
VAXIMM AG (“VAXIMM”) |  |  | 1,091,203,754 |  |  |  | 100.00 | % |  | Biotech (drug development) |  | Switzerland
RMC Co., Ltd. (“RMC”) |  |  | 35,000,000 |  |  |  | 100.00 | % |  | Medical device distribution |  | Republic of Korea
Darnatein Co., Ltd. (“Darnatein”) |  |  | 6,466,667,000 |  |  |  | 100.00 | % |  | Biotech (drug development) |  | Republic of Korea
OSR Holdings, Inc. |  |  | 2,826,969 |  |  |  | 100.00 | % |  | SPAC |  | The United States
Schedule of Key Financial Information | Key financial information of the subsidiaries at March 31, 2025 are as follows :
Name of subsidiary |  | Asset |  |  | Liability |  |  | Equity |  |  | Sales |  |  | Net Income (loss) |
VAXIMM AG |  | $ | 910,415 |  |  | $ | 386,254 |  |  | $ | 524,161 |  |  | $ | - |  |  | $ | (78,609 | )
RMC Co.,Ltd |  |  | 2,040,181 |  |  |  | 1,568,695 |  |  |  | 471,486 |  |  |  | 761,272 |  |  |  | (211,541 | )
Darnatein Co.,Ltd |  |  | 110,171 |  |  |  | 678,651 |  |  |  | (568,481 | ) |  |  | - |  |  |  | (141,742 | )
OSR Holdings, Inc. |  |  | 1,687,119 |  |  |  | 10,071,814 |  |  |  | (8,384,695 | ) |  |  | - |  |  |  | - |
Schedule of Summaries of Entities | Summaries of entities, which are newly included in consolidation scope for the periods ended March 31, 2025 and 2024 are as follows:
For the year ended March 31, 2025
Name of subsidiary |  | Reason |  | Type of purchase consideration
OSR Holdings, Inc. |  | Acquisition (*1) |  | Equity swap with shares of the Parent and OSR inc.’s share

X
- Definition Tabular disclosure of consolidation of entities. + References No definition available. + Details
Name: | osrh_ScheduleOfConsolidationOfEntitiesTableTextBlock
Namespace Prefix: | osrh_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The tabular disclosure of details of shareholders. + References No definition available. + Details
Name: | osrh_ScheduleOfDetailsOfShareholders
Namespace Prefix: | osrh_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The tabular disclosure of key financial information. + References No definition available. + Details
Name: | osrh_ScheduleOfKeyFinancialInformation
Namespace Prefix: | osrh_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership. + References No definition available. + Details
Name: | us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration